Inhibition of interleukin-5 mediated eosinophil viability by fluticasone 17-propionate: Comparison with other glucocorticoids

Clinical and Experimental Allergy

Volumn 28, Issue 8, 1998, Pages 999-1006

  Hagan, J B ^a   Kita, H ^a   Gleich, G J ^a,b  

^a MAYO CLINIC   (United States)

^b MAYO GRADUATE SCHOOL   (United States)

Author keywords

Cytokines; Dexamethasone; Eosinophil; Fluticasone 17 propionate; Glucocorticoids; Granulocyte macrophage colony stimulating factor; Hydrocortisone; Interferon ; Interleukin (IL) 5

Indexed keywords

BECLOMETASONE; BECLOMETASONE DIPROPIONATE; BUDESONIDE; DEXAMETHASONE; FLUNISOLIDE; FLUTICASONE PROPIONATE; GLUCOCORTICOID; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; HYDROCORTISONE; INTERLEUKIN 5; TRIAMCINOLONE;

ARTICLE; ATOPY; CELL VIABILITY; CONTROLLED STUDY; DRUG EFFECT; EOSINOPHIL; HUMAN; HUMAN CELL; PRIORITY JOURNAL;

ADMINISTRATION, INHALATION; ANDROSTADIENES; ANTI-INFLAMMATORY AGENTS; ASTHMA; CELL SEPARATION; CELL SURVIVAL; CELLS, CULTURED; DOSE-RESPONSE RELATIONSHIP, DRUG; EOSINOPHILS; FLOW CYTOMETRY; HUMANS; INTERLEUKIN-5; RHINITIS, ALLERGIC, SEASONAL;

EID: 0031709601     PISSN: 09547894     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2222.1998.00363.x     Document Type: Article

References (24)

1. Barnes PJ. Inhaled glucocorticoids for asthma. N Engl J Med 1995; 332:868-75.
2. Kerrebijn KF, van Essen-Zandvliet EE, Neijens HJ. Effect of long-term treatment with inhaled corticosteroids and betaagonists on the bronchial responsiveness in children with asthma. J Allergy Clin Immunol 1987; 79:653-9.
3. Juniper EF, Lein PA, Vanzieleghem MA et al. Effect of long-term treatment with an inhaled corticosteroid (budesonide) on airway hyperresponsiveness and clinical asthma in nonsteroid-dependent asthmatics. Am Rev Respir Dis 1990; 142:832-6.
4. Guidelines for the diagnosis and management of asthma. National Asthma Education Program Expert Panel Report. Bethesda, MD, Department of Health and Human Services, NIH Publication no. 91-3042, 1991: 35-43.
5. Gleich GJ, Frigas E, Loegering DA, Wassom DL. Steinmuller D. Cytotoxic properties of the eosinophil major basic protein. J Immunol 1979; 123:2925-7.
6. Gleich GJ, Loegering DA. Immunobiology of eosinophils. Ann Rev Immunol 1984; 2:429-59.
7. Frigas E, Loegering DA, Solley GO, Farrow GM, Gleich GJ. Elevated levels of the eosinophil major basic in sputum of patients with bronchial asthma. Mayo Clin Proc 1981; 56:345-53.
8. Gleich GJ. Eosinophil granule proteins and bronchial asthma. Allergol Int 1996; 45:35-64.
9. Gleich GJ, Hunt LW, Bochner BS, Schleimer RP. Glucocorticoid effects on human eosinophils. In: Schleimer RP, Busse WW, O'Byrne PM. eds Inhaled Glucocorticoids and Asthma: Mechanisms and Clinical Actions, Lung Biology in Health and Disease. New York: Marcel Dekker, Inc., Vol. 97, Chapter 13, 1996: 279-308.
10. Wallen N, Kita H, Weiler D, Gleich GJ. Glucocorticoids inhibit cytokine-mediated eosinophil survival. J Immunol 1991; 147:3490-5.
11. Lamas AM, Leon OG, Schleimer RP. Glucocorticoids inhibit eosinophil responses to granulocyte-macrophage colony-stimulating factor. J Immunol 1991; 147:254-9.
12. Hansel TT, DeVries IJM, Iff T et al. An improved immunomagnetic procedure for the isolation of highly purified human blood eosinophils. J Immunol Meth 1991; 145:105-10.
13. Ide M, Weiler D, Kita H, Gleich GJ. Ammonium chloride exposure inhibits cytokine-mediated eosinophil survival. J Immunol Meth 1994; 168:187-96.
14. Pullen GR, Chalmers PJ, Nind APP, Nairn RC. Criteria of cell killing in vitro. J Immunol Meth 1981; 43:87-93.
15. Harding SM. The human pharmacology of fluticasone propionate. Respir Med 1990; 84 (Suppl. A):25-9.
16. Brattsand R, Selroos O. Current drugs for respiratory diseases glucocorticosteroids. In: Metzger WJ, ed. Drugs and the Lung. New York: Raven Press, Ltd., Chp. 3, 1994: 101-220.
17. Würthwein G, Rehder S, Rohdewald P. Lipophilicity and receptor affinity of glucocorticoids. Pharm Ztg Wiss 1992; 137:161-7.
18. Dive C, Gregory CD, Phipps DJ et al. Analysis and discrimination of necrosis and apoptosis (programmed cell death) by multiparameter flow cytometry. Biochim Biophys Acta 1992; 1133:275-85.
19. Sun XM, Snowden RT, Skilleter DN et al. A flow-cytometric method for the separation and quantitation of normal and apoptotic thymocytes. Anal Biochem 1992; 204:351-6.
20. Butterfield JH, Ackerman SJ, Weiler D, Eisenhrey AG, Gleich GJ. Effects of glucocorticoids on eosinophil colony growth. J Allergy Clin Immunol 1986; 78:450-7.
21. Guida L, O'Heir RE, Hawrylowicz CM. Synergy between dexamethasone and interleukin-5 for the induction of major histocompatibility complex class II expression by human peripheral blood eosinophils. Blood 1994; 84:2733-40.
22. Kam JC, Szefler SJ, Surs W, Sher ER, Leung DY. Combination of IL-2 and IL-4 reduces glucocorticoid receptor-binding affinity and T cell response to glucocorticoids. J Immunol 1993; 151:3460-6.
23. Sher ER, Leung DY, Surs W et al. Steroid-resistant asthma: cellular mechanisms contributing to inadequate response to glucocorticoid therapy. J Clin Invest 1994; 93:33-9.
24. Ohnishi T, Kita H, Weiler D et al. IL-5 is the predominant eosinophil-active cytokine in the antigen-induced pulmonary late-phase reaction. Am Rev Respir Dis 1993; 147:901-7.